Clinical trials: Lung Cancer Patients
Neoplasms, Neoplasms, Glandular and Epithelial
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK)…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02909452
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Non-small Cell Lung Cancer
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules…
- Trial name
- NCT04273815
- Testing
- TQ-A3334, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer, Metastatic Cancer
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00738335
- Testing
- erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Sponsor
- University of California, San Francisco
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell…
- Trial name
- NCT06736418
- Testing
- 225Ac-ABD147
- Where
- 12 sites in United States
- Volunteers
- 17 people
- Sponsor
- Abdera Therapeutics Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Cancer, Covid-19
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
The purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.
- Trial name
- COV-IMMUNO (NCT04442048)
- Testing
- IMM-101, Observation
- Where
- 8 sites in Canada
- Volunteers
- 195 people
- Sponsor
- Canadian Cancer Trials Group
Carcinoma, Non-Small-Cell Lung
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting.
- Trial name
- NCT03456076
- Testing
- Alectnib, Cisplatin, Vinorelbine
- Where
- 114 sites in United States, Australia and 25 more
- Volunteers
- 257 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer, Fasting
Effect of Preoperative Oral Carbohydrate Administration in Thoracic Surgery Patients
Preoperative carbohydrate loading has been shown to reduce pre-operative discomfort and postoperative nausea and vomiting. There is no need for prolonged preoperative fasting of the patients, but the traditional approach still…
- Conditions
- Non Small Cell Lung Cancer, Fasting, Postoperative Pneumonia
- Trial name
- oralcarbohydra (NCT05005091)
- Testing
- Oral carbohydrate
- Where
- Turkey (Türkiye)
- Volunteers
- 94 people
- Sponsor
- Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital
Circulating Tumor Cells
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
The purpose of the study is to evaluate the association between the number of circulating tumor cells and response to treatment in non small-cell lung cancer patients
- Trial name
- NCT01052818
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- National Institute of Cancerología
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib hydrochloride and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Celecoxib may also stop the growth of lung cancer by blocking blood flow to the tumor.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00499655
- Testing
- erlotinib hydrochloride, celecoxib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.
- Trial name
- NCT01646450
- Testing
- Icotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Lung Cancer
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon…
- Trial name
- NCT00064350
- Testing
- Sorafenib
- Where
- 141 sites in United States
- Volunteers
- 342 people
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy…
- Trial name
- NCT00226590
- Testing
- Gemcitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non Small Cell Lung Cancer, Lung Cancer
Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer
Primary Objectives: The primary objectives of this study are as follows: To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of escalating ABT-751 in combination with fixed dose carboplatin in…
- Trial name
- NCT00735878
- Testing
- ABT-751 and Carboplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Konstantin Dragnev
Malignant Pleural Effusion
Tunneled Pleural Catheter in Partially Entrapped Lung
An open randomized, prospective, single center; parallel group trial to compare efficiency and safety of PleurX-Pleural Catheter versus standard surgical treatment in patients with malignant pleural effusion and partial…
- Trial name
- NCT00637676
- Testing
- VATS, Talc-Pleurodesis, tunneled pleural drainage, VATS, Talc-pleurodesis
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- PAINT (NCT02073968)
- Testing
- Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Albert Einstein College of Medicine
Carcinoma, Non-Small-Cell Lung
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
The purposes of this study are to determine: 1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2.
- Trial name
- NCT00034268
- Testing
- LY900003
- Where
- 105 sites in United States, Argentina and 19 more
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Detection Cell Free DNA in Lung Cancer Patients
third generation of EGFR-TKIs is the newest target therapy for NSCLC. However, we did not known the specific mechanisms for those non-responders and patients grow resistance.Next generation sequencing is current the most…
- Trial name
- NCT02738593
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
EGFR T790M, Osimertinib
Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
Liquid biopsy is emerging as an essential tool in tumor monitoring and a potential alternative and supplement to tissue biopsy for tumor genotyping, especially in relapsed or metastatic diseases.
- Conditions
- EGFR T790M, Osimertinib, Non-small Cell Lung Cancer, ddPCR
- Trial name
- NCT05458726
- Testing
- Osimertinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College
Lung Cancer
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00801385
- Testing
- erlotinib hydrochloride, sorafenib tosylate, DNA analysis
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Yonsei University